News / USA

US Launches Campaign Against Alzheimer's, Including Prevention Drug Trials

US Health and Human Services Secretary Kathleen Sebelius (file photo)US Health and Human Services Secretary Kathleen Sebelius (file photo)
US Health and Human Services Secretary Kathleen Sebelius (file photo)
US Health and Human Services Secretary Kathleen Sebelius (file photo)
Jessica Berman
The U.S. government has announced a major education and research campaign to fight Alzheimer's disease.  As part of that effort, scientists are stepping up their efforts to develop drugs by the middle of the next decade that could prevent the incurable brain-wasting disease.  

Two Alzheimer's disease prevention trials are receiving money from the National Institutes of Health, or NIH, as part of the Obama administration's new national strategy to fight the growing problem of Alzheimer's in the U.S. and around the world.  

An estimated 5.4 million Americans suffer from Alzheimer's or some form of dementia.  The number is expected to grow exponentially as the U.S. population ages, and reach 7.7 million by 2030.  By then, Alzheimer's and other dementia disorders could be affecting as many as 66 million people worldwide.

The so-called National Alzheimer's Plan calls on scientists to develop treatments to prevent the disease by 2025. NIH has set aside $50 million to help fund the effort.  NIH director Francis Collins says the studies herald a new era in Alzheimer's disease research.

"We have learned more about this disease in the last couple of years than probably ever before," said Collins. "And now the goal is to take that and translate it into interventions."

Collins was speaking at an NIH-sponsored conference of the nation's top Alzheimer's researchers.

Scientists at the Banner Alzheimer's Institute in Arizona announced they will be conducting human trials early next year of an experimental drug, called crenezumab, that they hope will prevent the disease.

The study will involve members of a large extended family living in remote villages within several hundred kilometers of each other near Medellin, Colombia.  Some of the thousands of relatives carry an extremely a rare genetic mutation that inevitably causes early on-set Alzheimer's.  

Those with the genetic flaw begin showing cognitive declines in their mid-forties and are destined to develop full-blown Alzheimer's by their early 50's.

The Banner Institute's Pierre Tariot is one of the lead investigators. Addressing the ethical questions some critics have raised about testing drugs on healthy people in a poor developing country, Tariot says all of the study participants have been fully informed about the possibility that the drug might not work, or that they might get a placebo that does not contain crenezumab.  

Tariot says they still wanted to participate.

"They have been faced with this devastating illness hitting every generation for hundreds of years," said Tariot. "As one of them put it, 'There are many rivers to cross but at least we are at the first bank.'  And that's kind of the attitude that people have had."

Three hundred individuals have signed up for the trial; one-third will receive crenezumab and the others will be given a placebo. The trial will also include a smaller number of individuals in the United States.

If the therapy works in those with early-onset disease, scientists hope it may also help older individuals.

Cremezumab is a vaccine that targets the brain plaques or amyloid protein deposits that are thought to underlie development of Alzheimer's, according to Banner's Eric Reiman, who will help lead the study.

"Crenezumab is an antibody treatment that is intended to bind with amyloid and remove it from the brain," said Reiman.

Injections of crenezumab or placebo will be administered every two weeks.  

The $100-million Colombia trial is slated to last five years, but researchers predict they could see results within two.  NIH is providing $16 million to support the research; Banner is contributing another $15 million.  The major share of the funding - about $65 million - will come from the drug's American manufacturer, Genentech.

A second Alzheimer's drug trial, also funded by NIH, has shown that a nasal insulin spray used twice daily by people with mild cognitive dysfunction seemed to improve their symptoms, offering hope that Alzheimer's could be treated or even prevented.

You May Like

Nearly Every Job in America Mapped in Detail

A nifty map pinpoints practically every job in the United States, revealing the economic character of America’s metropolitan areas, which also helps to inform the local culture

Corruption Busting Is Her Game

South African activist is building 'international online community of thousands of corruption fighters'

Former SAF Businessman Gives Books, Love of Reading to Students

Steve Tsakaris now involved in nonprofit Read to Rise, which distributes books in Soweto, encourages lower-grade primary school students to read

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
With HIV, Can We Get to Zero?i
Carol Pearson
November 29, 2015 1:23 PM
The theme of this year's World AIDS Day is "Getting to Zero." The U.N. says new HIV infections have been reduced by 35 percent since 2000 and AIDS-related deaths are down by 42 percent since the peak in 2004. VOA's Carol Pearson takes a look at what it might take to actually have an AIDS-free generation.

Video With HIV, Can We Get to Zero?

The theme of this year's World AIDS Day is "Getting to Zero." The U.N. says new HIV infections have been reduced by 35 percent since 2000 and AIDS-related deaths are down by 42 percent since the peak in 2004. VOA's Carol Pearson takes a look at what it might take to actually have an AIDS-free generation.

Video In Cambodian Capital, Political Motives Seen Behind Canceled Water Festival

For the fourth time in the five years since more than 350 people were killed in a stampede at Cambodia’s annual water festival, authorities canceled the event this year. Officials blamed environmental reasons as the cause, but many see it as fallout from rising political tensions with a fresh wave of ruling party intimidation against the opposition. David Boyle reports from Phnom Penh.

Video African Circus Gives At-Risk Youth a 2nd Chance

Ethiopia hosted the first African Circus Arts Festival this past weekend with performers from seven different African countries. Most of the performers are youngsters coming form challenging backgrounds who say the circus gave them a second chance.

Video US Lawmakers Brace for End-of-Year Battles

U.S. lawmakers are returning to Washington for Congress’ final working weeks of the year. And, as VOA's Michael Bowman reports, a full slate of legislative business awaits them, from keeping the federal government open to resolving a battle with the White House over the admittance of Syrian refugees.

Video Taiwan Looks for Role in South China Sea Dispute

The Taiwanese government is one of several that claims territory in the hotly contested South China Sea, but Taipei has long been sidelined in the dispute, overshadowed by China. Now, as the Philippines challenges Beijing’s claims in an international court at The Hague, Taipei is looking to publicly assert its claims. VOA’s Bill Ide has more from Beijing.

Video After Terrorist Attacks, Support for Refugees Fades

The terrorists who killed and injured almost 500 people around Paris this month are mostly French or Belgian nationals. But at least two apparently took advantage of Europe’s migrant crisis to sneak into the region. The discovery has hardened views about legitimate refugees, including those fleeing the same extremist violence that hit the French capital. Lisa Bryant has this report for VOA from the Paris suburb of Cergy-Pontoise

Video Syrian Refugees in US Express Concern for Those Left Behind

Syrian immigrants in the United States are concerned about the negative tide of public opinion and the politicians who want to block a U.S. plan to accept 10,000 Syrian refugees. Zlatica Hoke reports many Americans are fighting to dispel suspicions linking refugees to terrorists.

Video Thais Send Security Concerns Down the River

As Thailand takes in the annual Loy Krathong festival, many ponder the country’s future and security. Steve Sandford reports from Chiang Mai.

Video Islamic State Unfazed by Losses in Iraq, Syria

Progress in the U.S.-led effort to beat Islamic State on its home turf in Iraq and Syria has led some to speculate the terror group may be growing desperate. But counterterror officials say that is not the case, and warn the recent spate of terror attacks is merely part of the group’s evolution. VOA National Security correspondent Jeff Seldin has more.

Video Belgium-Germany Border Remains Porous, Even As Manhunt For Paris Attacker Continues

One of the suspected gunmen in the Nov. 13 Paris attacks, Salah Abdeslam, evaded law enforcement, made his way to Belgium, and is now believed to have fled to Germany. VOA correspondent Ayesha Tanzeem makes the journey across the border from Belgium into Germany to see how porous the borders really are.

Video US, Cambodian Navies Pair Up in Gulf of Thailand

The U.S. Navy has deployed one of its newest and most advanced ships to Cambodia to conduct joint training drills in the Gulf of Thailand. Riding hull-to-hull with Cambodian ships, the seamen of the USS Fort Worth are executing joint-training drills that will help build relations in Southeast Asia. David Boyle reports for VOA from Preah Sihanouk province.

Video Uncertain Future for Syrian Refugee Resettlement in Illinois

For the trickle of Syrian refugees finding new homes in the Midwest city of Chicago, the call to end resettlement in many U.S. states is adding another dimension to their long journey fleeing war. Organizations working to help them integrate say the backlash since the Paris attacks is both harming and helping their efforts to provide refugees sanctuary. VOA's Kane Farabaugh reports.

VOA Blogs